NYSE:NBY NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis $0.67 +0.02 (+3.24%) As of 07/25/2025 03:57 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About NovaBay Pharmaceuticals Stock (NYSE:NBY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NBY alerts:Sign Up Key Stats Today's Range$0.65▼$0.6950-Day Range$0.55▼$0.6952-Week Range$0.36▼$1.01Volume116,930 shsAverage Volume114,704 shsMarket Capitalization$3.91 millionP/E RatioN/ADividend YieldN/APrice Target$0.85Consensus RatingBuy Company Overview NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Read More NovaBay Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreNBY MarketRank™: NovaBay Pharmaceuticals scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNovaBay Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNovaBay Pharmaceuticals has received no research coverage in the past 90 days.Read more about NovaBay Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($3.26) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovaBay Pharmaceuticals has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NBY. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovaBay Pharmaceuticals does not currently pay a dividend.Dividend GrowthNovaBay Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for NBY. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for NBY on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of NovaBay Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 23.25% of the stock of NovaBay Pharmaceuticals is held by institutions.Read more about NovaBay Pharmaceuticals' insider trading history. Receive NBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NBY Stock News HeadlinesNBY NovaBay Pharmaceuticals, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comNovaBay Pharmaceuticals Inc. Stock Grades | NBY | Barron'sMay 26, 2025 | barrons.comTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trillion U.S. manufacturing boom. Dubbed Trump’s “New Golden Age” tech, this breakthrough has drawn praise from Elon Musk and NVIDIA’s CEO—and early investors may have a rare chance to get in ahead of the crowd.July 26 at 2:00 AM | Brownstone Research (Ad)NovaBay Pharmaceuticals approves liquidation planApril 24, 2025 | uk.investing.comNovaBay Pharmaceuticals Delays Yearly Report FilingApril 1, 2025 | tipranks.comNovaBay Pharmaceuticals to Hold Special Meeting of StockholdersMarch 7, 2025 | businesswire.comNovaBay fails to gain shareholder approval for dissolutionFebruary 5, 2025 | msn.comNovaBay Pharmaceuticals Inc NBYFebruary 1, 2025 | morningstar.comMSee More Headlines NBY Stock Analysis - Frequently Asked Questions How have NBY shares performed this year? NovaBay Pharmaceuticals' stock was trading at $0.6010 at the start of the year. Since then, NBY stock has increased by 11.9% and is now trading at $0.6724. How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NYSE:NBY) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.32. The business earned $2.44 million during the quarter, compared to the consensus estimate of $2.50 million. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 7,293.78% and a negative net margin of 102.72%. When did NovaBay Pharmaceuticals' stock split? NovaBay Pharmaceuticals's stock reverse split before market open on Friday, May 31st 2024.The 1-35 reverse split was announced on Friday, May 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are NovaBay Pharmaceuticals' major shareholders? Top institutional investors of NovaBay Pharmaceuticals include C2C Wealth Management LLC (1.69%). View institutional ownership trends. How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Adverum Biotechnologies (ADVM), American Resources (AREC), Clearside Biomedical (CLSD), Hello Group (MOMO), Palatin Technologies (PTN), Xeris Biopharma (XERS) and Algonquin Power & Utilities (AQN). Company Calendar Last Earnings11/07/2024Today7/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NBY CIK1389545 Webnovabay.com Phone510-899-8800Fax510-474-1577Employees30Year FoundedN/APrice Target and Rating Average Price Target for NovaBay Pharmaceuticals$0.85 High Price Target$0.85 Low Price Target$0.85 Potential Upside/Downside+26.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($53.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.64 million Net Margins-102.72% Pretax Margin-99.12% Return on Equity-7,293.78% Return on Assets-158.41% Debt Debt-to-Equity RatioN/A Current Ratio1.15 Quick Ratio0.91 Sales & Book Value Annual Sales$9.78 million Price / Sales0.40 Cash FlowN/A Price / Cash FlowN/A Book Value$4.25 per share Price / Book0.16Miscellaneous Outstanding Shares5,816,000Free Float4,881,000Market Cap$3.91 million OptionableNot Optionable Beta0.44 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NYSE:NBY) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.